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Introduction: It is estimated that incidence of urinary tract infec-
tions (UTI) in a whole world is ~150 million per year. In Health 
center Novi Sad (out hospital care), UTIs are after respiratory tract 
infections most common reason for prescribing antibiotics. Usual 
practice is empiric treatment of UTIs, while urine analysis is done 
in case of empiric treatment failure, recurrent or complicated UTIs. 
Most common pathogen in UTIs is Escherichia coli. The aim of the 
study was to analyze prescribing habits, compliance of prescribing 
with national guidelines, and local resistance of isolated bacteria.
Patients (or Materials) and Methods: Novi Sad Health center offers 
health services to a population of ~385,000 inhabitants. Study was 
done in period from January – December 2012. Data on drug pre-
scribing and most common bacteria isolated from urine samples were 
collected, analyzed, and compared with national guidelines on treat-
ment of UTIs.
Results: Of about 20,000 urine samples analyzed, ~30% were 
positive. The most common bacteria isolated were E coli (~70%), 
Proteus mirabilis, Klebsiella pneumoniae, and Enterococcus species, 
all 3 with ~8% incidence. There were ~40,000 prescriptions for the 
treatment of UTIs. Most frequently prescribed drug was cefalexine 
(~30%), followed by ciprofloxacin (~25%), pipemidic acid (~13%), 
co-trimoxazole (~11%), and amoxicilline + clavulic acid (~4%).
Conclusion: Deviations in prescribing habits regarding the national 
guidelines include: (1) most frequently prescribed drug is cefalexine, 
recommended only in case of allergy to sulpha-derivates, and if fluo-
roquinolones are contraindicated; additional problem is decreased 
sensitivity to cefalexine in most frequently isolated bacteria E coli, 
61.75%; P mirabilis, 52.69%; K pneumonia, 47.44%; (2) although 
the resistance of E coli to co-trimoxazole is > 20% (32%), it is still 
prescribed for treatment of UTIs (11% of all prescriptions; and (3) 
other isolated bacteria, except E coli, have sensitivity of ≤50% to 
most of the recommended drugs. These data indicate that there exists 
a necessity to harmonize national guidelines with local resistance of 
bacteria. After harmonization, medical doctors should be instructed 
to follow the national guidelines in order to control bacterial resist-
ance and assure positive therapeutic outcome.
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Introduction: Alzheimer’s disease (AD) is a progressive disorder in 
which brain cells (neurons) deteriorate, resulting in the loss of cog-
nitive functions, primary memory, judgment, reasoning, movement 
coordination, and pattern recognition. This study was designed to 
investigate the effect of α -chymotrypcin (α -ch) on management of 
AD in an experimental model.
Patients (or Materials) and Methods: Sixty adult female albino rats 
were divided into 4 groups each of 15 rats: (1) normal control rats 
(con group); (2) rats underwent surgery to remove ovaries (Ovx 
group); (3) ovariectomized group received aluminum chloride in 
a dose of 17 mg/kg daily, orally for 2 months, to induce AD (AD 
group); and (4) AD group treated with α -chymotrypcin at dose (8.1 
unit/rat/d IM) for 3 months (α -ch). At the end of the experimental 
period, rats were sacrificed; brain samples were obtained for dif-
ferent biochemical analyses and histopathologic examination. The 
biochemical analyses included determination of transforming growth 
factor-β (TGF-β ), brain-derived neurotrophic factor (BDNF), and 
vascular endothelial growth factor (VEGF).
Results: In comparison with the normal control group, the Ovx 
group recorded significant increase in the brain level of TGF-β , while 
the brain levels of BDNF and VEGF were significantly decreased. 
Similarly, AD group recorded significant increase in the brain level 
of TGF-β accompanied with significant decrease in brain BDNF and 
VEGF levels compared with the Ovx group. However, the treatment 
of the AD group with α -chymotrypcin resulted in an improvement in 
the biochemical parameters which reflected by decreased brain level 
of TGF-β accompanied with a significant increase in the brain levels 
of BDNF and VEGF, compared with AD group. Histopathologic 
investigation of brain tissue of Ovx rats administered with aluminum 
showed AD plaques indicating the validation of AD model. While, 
AD group treated with α -chymotrypcin showed great improvement 
in the brain morphological structure and disappearance of most of 
amyloid plaques.
Conclusion: This study revealed that the treatment of AD rats with 
α -chymotrypcin significantly ameliorates the neurodegeneration as 
well as modulates the essential growth factor in the brain of AD 
model due to its proteolytic activity, anti-inflammatory effect, and 
antioxidant capacity.
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Introduction: Large observational studies in patients with type 2 
diabetes mellitus (DM) have demonstrated that metformin treatment 
improves cardiovascular prognosis, independent of glycemic control. 
Subsequent animal studies, both in animals with and without DM, 
have indeed shown that metformin has direct acute cardioprotective 
effects. Whether metformin also limits ischemia-reperfusion (IR)-
injury in humans is currently unknown. Therefore, in this study, we 
examined whether metformin treatment limits IR injury in a forearm 
model of endothelial IR-injury in healthy middle-aged volunteers.
Patients (or Materials) and Methods: Twenty-six healthy volunteers 
(age, 41 [6] years; 10 male/16 female), were randomized between 
pretreatment with metformin 500 mg 3 times a day for 3 days or no 
medication in a randomized crossover trial with a washout period 
of 2 weeks. Brachial artery flow-mediated dilation (FMD) was meas-
ured using high-resolution Doppler ultrasound before and after 20 
minutes of forearm ischemia and 20 minutes of reperfusion. Brachial 
Clinical Therapeutics
e42 Volume 35 Number 8S
artery FMD represents a largely nitric oxide-mediated, endothelium-
dependent dilation and is attenuated by preceding forearm IR. FMD 
is a well-validated model to study IR-injury in humans. Forearm 
ischemia was induced by inflating a blood pressure cuff around the 
upper arm level. FMD analysis was performed offline by investigators 
blinded to the treatment arm.
Results: Baseline FMD did not differ between metformin pretreat-
ment and no pretreatment (6.9% [3.6%] and 6.1% [3.5%], respec-
tively; P = 0.27). FMD was significantly lower after forearm IR in 
both treatment arms (4.4% [3.3%] and 4.3% [2.8%], respectively; 
P < 0.01 in both groups). A 2-way repeated measures ANOVA 
revealed that metformine treatment did not prevent the decrease in 
FMD by IR (P = 0.50).
Conclusion: In this study, we investigated for the first time whether 
treatment with metformin limits IR-injury in humans in vivo. In con-
trast with previous studies in animal models of myocardial infarction, 
we did not observe any protective effect of metformin on endothelial 
IR-injury, measured with brachial artery FMD, in healthy middle-
aged volunteers. Our study does not exclude that metformin has pro-
tective effects in patients with cardiovascular disease or patients with 
DM. As such, additional studies, including studies in these patient 
groups, are needed to explore the discrepancy between the previous 
preclinical findings and our current results.
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Introduction: Ticagrelor is a P2Y12 receptor antagonist, with supe-
rior effects but also ensuing enhanced bleeding risk compared with 
clopidogrel. Determination of platelet inhibition may be useful to 
confirm efficient platelet inhibition on an individual patient level and 
to identify patients at risk for bleeding, particularly in a preopera-
tive setting. The vasodilator-associated stimulated phosphoprotein 
(VASP) phosphorylation assay specifically measures platelet P2Y12 
inhibition but has so far required special flow cytometric equipment 
and individual sample processing. A new ELISA-based VASP assay 
has been developed that allows batch analysis after initial platelet 
activation. Due to the reversible binding of ticagrelor, it is unclear if 
the ELISA and flow cytometric assays provide comparable results.
Patients (or Materials) and Methods: We hypothesized that the con-
ventional and new methods may be comparable when the revers-
ible P2Y12 inhibitor ticagrelor is used. We pair-wise compared the 
platelet reactivity index (PRI) between assays in a prospective clinical 
trial. Healthy volunteers received a single 180-mg loading dose of 
ticagrelor.
Results: PRI-values of the 2 methods correlated well (r = 0.97, P < 
0.001). Ticagrelor rapidly decreased PRI values on average after 50 
minutes, but nadir levels 2 to 6 hours after ticagrelor intake were 
15% higher when PRI% was measured with the flow cytometric 
method. Bland-Altman analysis showed that the flow cytometric 
assay measured markedly higher PRI levels than the new ELISA-
based technique (mean difference, 13%).
Conclusion: The new ELISA-based VASP assay offers an alternative 
to the currently used flow cytometric method, but measures lower 
PRI levels, particularly when PRI falls below 20% after ticagrelor 
intake.
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Introduction: Primary aldosteronism (PA) is the most prevalent form 
of endocrine hypertension, due to autonomous aldosterone produc-
tion. The 2 main causes of PA are aldosterone-producing adenome 
(APA) and bilateral adrenal hyperplasia (BAH). Aldosterone, syn-
thesized and secreted by the zona glomerulosa (ZG) of the adrenal 
gland, is physiologically regulated by angiotensin II (AngII), plasma 
potassium concentration [K+], and ACTH. However ,the molecu-
lar mechanisms that lead to the aldosterone hyperproduction are 
not completely understood. Recent studies have show the presence 
of somatic mutations of the inwardly rectifying potassium channel 
(KCNJ5) gene in APA, coding for the K+ channel KCNJ5. These 
mutations lie near or within the selectivity filter of the Kir3.4 channel, 
changing the normal Na+/K+ permability of the channel. Mutation-
scanning studies conducted on an Australian cohort with PA has 
identified germline single nucleotide polymorphisms (SNP) in the 
KCNJ5 gene (Q282E, E246K, and G247R) that may be relevant to 
the pathophysiology of PA in these subjects. However, the functional-
ity of these SNPs is unknown, so we have tested this directly.
Patients (or Materials) and Methods: The electrophysiology of these 
mutants was studied by applying a 2-electrode voltage clamp tech-
nique to Xenopus oocytes expressing the mutant KCNJ5 channels. A 
human H295R adrenocortical cell line was used as the experimental 
model to study the effects of the mutations on aldosterone release. 
Cells were transiently transfected with the WT KCNJ5 or mutant 
forms, and the aldosterone release was evaluated using a radioim-
munoassay, both under normal conditions and after depolarization 
with high extracellular K+ and Ang II.
Results: The Q282E and E246K KCNJ5 showed change in the selec-
tivity of the channel, with Na+ currents being observed in both of 
them. However, the G247R KCNJ5 behaved like the WT KCNJ5 
channel. Differences were also observed in the levels of aldosterone 
release from H295R cells expressing the different mutations, the 
details of which will be presented in the poster.
Conclusion: The findings from this work suggest that SNPs and 
rare variants outside the selectivity filter of KCNJ5 are functionally 
important and may be have a role in the autonomous aldosterone 
release in subjects with PA.
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Introduction: Hypoglycemic activity is one of the most important 
features of insulin derivatives and can be examined both in vitro and 
in vivo. The aim of the study was to evaluate activity of a new long-
acting insulin analogue using 3 different test systems.
